Skip Global navigation and goto content

It's a New Day in Public Health.

The Florida Department of Health works to protect, promote, and improve the health of all people in Florida through integrated state, county, and community efforts.

Skip MegaMenu and goto content

Alachua County Monoclonal Antibody Therapy Treatment Site Update

By DOH Alachua Staff

November 09, 2021

Gainesville, Fla. - The State of Florida successfully deployed and expanded state-run, lifesaving monoclonal antibody therapy treatment sites statewide. Throughout this process, the State has worked with a robust network of community partners to ensure the health care sector is equipped to administer monoclonal antibody therapy treatment to Floridians.

To support this transition of monoclonal antibody therapy treatment administration to locally operated providers, the state-supported monoclonal antibody therapy treatment site at Fellowship Church of High Springs, 16916 NW US Hwy 441 in Alachua County, will close on November 12, 2021.

Alternative monoclonal antibody therapy treatment locations in this area are listed below:

UF Health Shands Hospital
1600 SW Archer Rd
Gainesville, Florida
North Florida Regional Medical Center
6500 Newberry Rd
Gainesville, Florida
Infectious Disease Associates & Travel Medicine
3600 NW 43rd St. Ste D2
Gainesville, Florida

The Florida Department of Health will continue to allocate doses of monoclonal antibodies to health care providers with high utilization rates and will ensure inventory levels meet county demand.

Monoclonal Antibody Therapy Treatment Locator:

Monoclonal antibody therapy treatment locations can be found at and by using the National Infusion Center Association's treatment locator.

Benefits of Treatment:

Monoclonal antibodies help the immune system recognize and respond effectively to the COVID-19 virus.

Monoclonal antibody therapy treatment is for individuals who have contracted or been exposed to COVID-19. Monoclonal antibody therapy treatment can prevent severe illness, hospitalization, and death in high-risk patients who have contracted COVID-19. Specifically, it: 

  • Reduces the risk of death/hospitalization by 70%-85%.
  • Reduces the risk of developing symptomatic disease by over 80%.



Statewide Articles

JavaScript must be enabled in your browser to display articles

Local Articles